¿Por qué y cómo tener en cuenta al cannabis en nuestros pacientes fumadores?

Mostra el registre complet Registre parcial de l'ítem

  • dc.contributor.author Olano Espinosa, Eduardo
  • dc.contributor.author Lozano Polo, Adelaida
  • dc.contributor.author Grifell Guardia, Marc
  • dc.contributor.author Pinet Ogué, María Cristina
  • dc.contributor.author Isorna Folgar, Manuel
  • dc.contributor.author Moreno Arnedillo, José Javier
  • dc.contributor.author Proyecto ÉVICT 1
  • dc.date.accessioned 2019-03-07T08:16:48Z
  • dc.date.available 2019-03-07T08:16:48Z
  • dc.date.issued 2018
  • dc.description.abstract EVICT project has noted the increase in cannabis use in the Spanish youth population, and has studied its association with tobacco, concluding that: It has an influence in the learning to smoke process: The beginning can be combined and with bi-directional influence. It has an influence on dependence the development of dependence Their interaction is relevant in the development of dependence. It has an influence on toxicity: Smoking tobacco and cannabis generates greater problems than smoking tobacco alone. And, therefore, the EVICT team issues some considerations: Prevention considerations. Differentiate between therapeutic and recreational use. Smoking cannabis is not therapeutic nor innocuous, and can affect the development of nicotine dependence, or, less frequently, cannabis dependence. Approach and treatment considerations. In A first option of cessation of both must be proposed in people who consume tobacco and cannabis Harm Reduction. To those that only consume tobacco/cannabis: Harm Reduction programs should be more applicable to those in whom consumption is considered more problematic.
  • dc.format.mimetype application/pdf
  • dc.identifier.citation Olano Espinosa E, Lozano Polo A, Grifell Guàrdia M, Pinet Ogué MC, Isorna Folgar M, Moreno Arnedillo JJ. Et al. ¿Por qué y cómo tener en cuenta al cannabis en nuestros pacientes fumadores?. Aten Primaria. 2020; 52(1): 47-53 DOI: 10.1016/j.aprim.2018.05.014
  • dc.identifier.doi http://dx.doi.org/10.1016/j.aprim.2018.05.014
  • dc.identifier.issn 0212-6567
  • dc.identifier.uri http://hdl.handle.net/10230/36772
  • dc.language.iso spa
  • dc.publisher Elsevier
  • dc.relation.ispartof Atención Primaria. 2020;52(1):47-53
  • dc.rights © 2018 Los Autores. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/)
  • dc.rights.accessRights info:eu-repo/semantics/openAccess
  • dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
  • dc.subject.keyword Atención primaria
  • dc.subject.keyword Cannabis
  • dc.subject.keyword Primary care
  • dc.subject.keyword Smoking
  • dc.subject.keyword Tabaquismo
  • dc.subject.other Tabaquisme
  • dc.subject.other Cannabinoides -- Efectes fisiològics
  • dc.title ¿Por qué y cómo tener en cuenta al cannabis en nuestros pacientes fumadores?
  • dc.type info:eu-repo/semantics/article
  • dc.type.version info:eu-repo/semantics/publishedVersion